Abstract Objective: There is at present no comprehen-
Introduction
The development of centralised drug licensing in the European Union is an example of the harmonisation of European institutions [1, 2] . This follows from a system of individual national licensing agencies acting independently that has not entirely disappeared but which is far less important than before. A result of this previous system is that many older drugs are available in only one or some of the European states but not in others, or that the doses and indications may vary between countries. Other discrepancies have existed and continue to exist in the patterns of drug use with relatively few drugs being widely used in more than one country [3, 4] , in expenditure on medication and in drug prices. Some of the most widely used medicines in some countries have even been withdrawn or were never licensed in others. There is rarely any scienti®c rationale for these discrepancies.
A system of improved communication between national and pan-European regulatory agencies and the pharmaceutical industry was proposed in the early 1990s [5] , particularly with regard to regulatory activity, pharmacovigilance and medicinal product authorisations. The general public was to have access to this information. Part of this was a directory of medicines, the European Product Index (EPI), itself a by-product of the European Community Pharmaceutical Information project [6] . The aims of this project were to ensure market transparency [7] , support pharmacovigilance and provide technical information by creating a repertory of drugs available in the European Union. Early trials suggested that the system would be of great value, but various diculties have meant that the EPI has never been developed. European regulatory agencies depend on a drug dictionary produced by the World Health Organization (WHO) and on a commercial directory produced by a for-pro®t organisation. The former, although useful, does not contain dosage form and some other information. The latter is not available to other groups except at great expense.
Identifying the discrepancies in availability of medicines can therefore be dicult, since at present there exists no directory of all medicines available in each European state. Such a directory would be of value to regulatory agencies, to those agencies negotiating drug prices, to manufacturers and those charged with promoting good prescribing. Other potential users of such a directory would be those with direct responsibility for patient care who need to identify the medicines a patient is using and consumers. To ®ll this gap, we undertook the``EURO-Medicines'' project, funded by the Commission of the European Communities under the IV Research programme (Biomed 2-Area 6, Public Health). Its aims were to de®ne drugs available in member states and, using these data, to compare the performance of each member state in regulating its drug market. The objectives (tasks) of this project were threefold:
· Task 1 ± to undertake a comprehensive survey of all medicines marketed in each of the 15 European Union members · Task 2 ± to examine selected medicines identi®ed from the list developed in task 1 as being available in most or all countries by reviewing the summary of product characteristics (SPC), since this represents the uses of the medicines approved in each state by the regulatory agencies · Task 3 ± to list active ingredients withdrawn for reason of safety or ineectiveness from any of the countries identi®ed from ocial lists and from published data and to examine if these ingredients were still available in other countries This paper describes task 1.
Methods
Each medicine was to be classi®ed by the WHO Anatomical Therapeutic Chemical (ATC) code [8] and identi®ed by international non-proprietary name of its active ingredients. Other information to be recorded was the proprietary name (with details such as pharmaceutical form, strength and pack size), the marketing authorisation holder, the year of approval, whether reimbursed by the health service, prescription status (hospital only, prescription only, over-the-counter) and any special restrictions on its use (e.g. for opiates or other controlled drugs). Unbranded or generic medicines were treated in the same way with the exception of the proprietary name. Utilisation data and prices were also recorded when available. The census period for these lists was the second half of 1998. A number of methodological diculties were anticipated. We expected diculty in ®nding complete national databases of good quality, despite a European requirement to have such a list available in each state [9] . We therefore aimed to use a variety of agencies in each of the member states to compile a list of available medicines, largely national formularies and also data from Ministries of Health or other national organisations, public or commercial as necessary. We also expected the data from such diverse sources to be of varying quality, and for quality assurance and standardisation of the data we followed the European Prestandard ENV 12610 (Medical Informatics ± Medicinal Product Identi®cation) [10] .
Further diculties were the de®nitions of what constituted a medicine. For licensed drugs, this is clear but for many over-thecounter (OTC) preparations, the distinction may be dicult. For OTC preparations such as vitamins, we decided to include a preparation only if we considered that it was clearly used therapeutically, and not as a simple food supplement, based on listing in the British National Formulary or similar source. Similarly, we decided to exclude herbal and homeopathic preparations where the range of products available varies enormously across Europe. We generally accepted the ATC code assignment on a national list where available, but for some countries it was necessary to undertake the assignment. The data were analysed using commonly available software (MS Excel 97 and Access 97).
Results
Data were received from a variety of sources. For only one country (Greece) was it not possible to obtain data. No source had all the information required, and the sources ranged from national lists provided by state agencies to prescribing databases, compendia of summaries of product characteristics, as well commercial directories of available medicines (Table 1 ). There are no data available at present on dermatological preparations in Portugal. The data on trade names for Austria, Belgium and Germany include not only the proprietary name but also the formulation and strength; these data are therefore not directly comparable to the data for the other countries which include only the proprietary name.
Numbers of medicines available
The numbers of medicines available varied widely among countries, with Germany having the largest number of both active ingredients (by ATC codes) and trade names and the Scandinavian countries the least ( Table 2 ). The average ratio between trade names and active ingredients is higher in Germany than in other countries. Details by ATC code (1st level) are shown in Table 3 .
Similarities and discrepancies between countries
The similarities and discrepancies between countries were further explored. Table 4 shows what percentage of the ingredients licensed in each country is available in the other countries, for those countries for which complete data are available. More than 60% of the ingre-dients licensed in the Scandinavian countries are available in all the other states. The extreme ®gures are for Germany and Sweden: 83% of the active ingredients licensed in Sweden are available in Germany, but only 42% of the ingredients approved in Germany are available in Sweden. Only 7% of all the active ingredients are available in all the participating countries. The percentage diers among ATC classes: high for antineoplastic agents, systemic hormones (both 18%) and antiinfective agents (12%), low for dermatological agents, antiparasitic agents and various (1% each or less) and nootropics (none mutually available).
Number of exclusively available medicines
In each country, there is a small number of active ingredients exclusive to that country. Table 5 shows the number of drugs exclusively available in only one country for some ATC groups for those countries for which data are available.
Speci®c therapeutic areas
The data allow more speci®c examination of individual therapeutic areas. For instance, the numbers of active principles and available preparations in each of the major classes of cardiovascular or neurological medicines can be compared in each country. Table 6 shows the range of drugs within a particular class within each country, i.e. beta blockers, ACE inhibitors, peripheral vasodilators or nootropics (e.g. piracetam).
Discussion
We developed a directory of medicines available in the European Union at a single point in time. This directory lends itself to many analyses of which this paper presents only a small number. More detailed examination of this database will be of value to a range of bodies as suggested above. This database is available now to interested parties (regulatory bodies and academic research) and we intend to make it more widely available on a website (www.euromedicines.org). Its updating and maintenance as medicines are licensed and withdrawn would considerably enhance the value of this data source, and we intend to undertake this work periodically. Austria  217  101  231  158  105  38  173  82  89  217  15  137  86  77  1727  Belgium  191  75  166  132  98  26  147  69  63  210  22  128  104  51  1483  Denmark  103  62  119  81  62  22  96  60  53  162  19  70  56  51  1016  Finland  130  60  118  78  72  20  116  73  60  144  11  75  66  107  1130  France  197  82  172  135  104  33  151  79  68  198  42  135  79  39  1514  Germany  256  124  269  184  119  40  178  101  91  258  28  141  116  82  1974  Ireland  219  75  138  141  64  31  125  68  60  192  15  103  70  51 for systemic use, L anti-neoplastic and immunomodulating agents, M musculoskeletal system, N nervous system, P anti-parasitic products, insecticides and repellents, R respiratory system, S sensory organs, V various Austria  100  59  49  51  81  51  60  63  57  53  48  54  Belgium  72  100  55  54  79  60  67  82  66  61  52  60  Denmark  81  73  100  75  84  67  69  76  76  65  73  71  Finland  78  67  70  100  79  61  68  71  69  60  70  67  Germany  68  54  43  44  100  47  54  59  50  49  42  49  Ireland  65  63  53  51  72  100  58  64  59  55  50  66  Italy  62  56  43  45  66  46  100  58  50  54  42  50  Luxembourg  71  75  52  52  79  56  63  100  60  58  49  57  Netherlands  80  76  65  63  84  65  69  75  100  63  61  69  Spain  69  65  51  51  75  55  68  66  58  100  48  59  Sweden  79  71  74  76  83  65  69  73  72  62  100  70  U K  6 8  6 2  5 5  5 5  7 3  6 5  6 2  6 4  6 2  5 8  5 3  1 0 0 The range of drugs available in each country represents dierences in regulatory and market policies, as well as cultural and historic dierences [2] . This is not to necessarily imply that a decision in one country is better than another but to raise questions that require explanation. In the UK, for instance, the government has encouraged generic prescribing that in turn promotes the production of more preparations of widely used medicines, often unbranded, that are less expensive than the major-branded forms. Such generic or unbranded forms are not well documented in standard reference sources but were all included in our directory. There may also be dierences in medical culture and diagnosis, for instance the wide dierences in rates of prescribing with higher rates in Mediterranean countries and lower in Scandinavia [2, 11] or a diagnosis of systemic hypotension in Germany which is rarely made in the UK [2] . Garattini [3, 4] attributes the diering patterns of use of medicines in major European markets to the in¯uence of promotion by national pharmaceutical companies, the lack of adequate training of physicians in clinical pharmacology and the lack of reliable comparative clinical data to allow clinicians to distinguish between more expensive`m e-too' drugs and their prototypes. This has resulted in the past in 20% of expenditure in Italy or France going for drugs considered to be of little or no proven therapeutic bene®t [12, 13] . Both countries have since taken drastic action to redress this situation, but discrepancies still exist [14] .
The discrepancies in the market originate at least in part with discrepancies in the medicines available in each country. These discrepancies may take a number of forms. Medicines may be licensed in some countries but not in others, as shown in this article. Others may be withdrawn for safety reasons from some countries, but may be among the best-selling and most widely used drugs in other countries (e.g. dipyrone was withdrawn in many countries but is widely used in Spain). There may also be dierences in the indications for older drugs across national boundaries (e.g. trimetazidine is used for angina in France and for Meniere's disease in Denmark). It is dicult to keep track of new products, indications, contraindications and adverse drug reactions within one country, but with such wide variations in medicines licensed and the terms of the licence, the increasing movement of patients or health care profes- Austria  1  11  1  3  0  0  2  4  10  1  2  Belgium  0  3  3  0  1  0  0  0  7  0  0  Germany  0  17  5  5  3  0  5  5  14  2  3  Denmark  0  0  1  1  0  0  1  0  1  0  0  Finland  2  1  2  0  0  0  1  0  3  0  0  France  0  10  8  4  4  0  0  2  19  0  0  Italy  2  30  9  4  9  1  3  4  25  2 sionals across national boundaries will cause many problems. The lack of a comprehensive database of available products compounds this. The diculties of creating this database were greater than initially anticipated. An important weakness in our data is the lack of uniformity between countries in the assignment of ATC code, particularly for the active ingredients with more or many ATC codes. To explore this problem, a comparative analysis of ATC assignment in European countries has been planned in co-operation with the WHO-Oslo Centre. Another weakness in the data is the diculties of de®ning numbers of OTC or general-sales-list preparations, and this may explain a small amount of the variation in number of preparations between countries.
Some countries had only an incomplete or even no national list available from government sources, despite a European Union (EU) directive [9] . The EU recognises the need for product information of the type in our database. An initiative of the European Medicines Evaluation Agency, the Medicines Information Network for Europe [15] , is attempting to improve market transparency within the EU by harmonising the product information available in the EU. Its aims are to make available all SPCs and any Patient Information Lea¯ets in all EU ocial languages in an electronic database, regularly updated. It does not attempt to harmonise medical practice, nor to move too quickly to a single European pharmaceutical market [16] . A pilot project is to be undertaken by the European Joint Research Centre between 2000±2002, initially only for those products approved by the European Commission under the centralised and mutual recognition procedures. It will be some years before any results are seen. Its content and coverage dier from that in our database. As mentioned earlier, a previous attempt to establish a directory similar to EURO-Medicines as part of the European Union Drug Regulatory Agencies Network was unsuccessful.
A further advantage of our database is that it was developed in parallel with another database covering most of the countries of central and eastern Europe preparing to join the EU in another project funded by the European Commission (CEE-Medicines, Folino P). This will allow EURO-Medicines to be rapidly expanded to keep pace with the future expansion of the EU.
The advantages of such databases extend beyond supporting clinicians and promoting harmonisation of information and availability of medicines. Better knowledge of the current situation in other countries can be the foundation for new policy decisions constructed in the best interest of the patient. Such databases are therefore of interest to both European and national policy makers as well as to regulatory agencies, the WHO, consumer groups and pharmaceutical industry associations. Our database may allow countries to identify and address concerns about availability of medicines or to identify where and how they can improve their work, especially where benchmarking against other states suggests that patients are being exposed to dangerous or ineective therapies. This may lead to a substantial improvement in the quality of care and therapeutic outcome and a signi®cant improvement in the eciency of the health systems.
